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EFFECTS OF PREPARATIVE REGIMENS ON HOST DENDRITIC CELLS
PRE-TRANSPLANT IN ALLOGENEIC STEM CELL TRANSPLANTATION
Chan, G.W.1, Betancur, M.1, Sprague, K.A.1, Klein, A.K.1 1Tufts-New
England Medical Center, Boston, MA.
Background: Host dendritic cells(DCs) present antigens to
donor T-cells, thereby initiating graft-vs-host disease (GVHD)
in allogeneic stem cell transplantation. The effects of prepara-
tive regimens on host DCs remain unknown. We prospectively
studied changes in host DC populations pre-transplant. Meth-
ods: 17 patients, median age 47 years, with various hematologic
malignancies underwent a conventional preparative regimen of
cyclophosphamide 120mg/kg and 1200cGy total body irradia-
tion (TBI) (n8) or a reduced intensity preparative regimen of
extracorporeal photopheresis (ECP) x 2 days, pentostatin
8mg/m2 by continuous iv infusion over 48 hours, and 600cGy
TBI (n9), followed by allogeneic stem cell transplantation
from fully matched related (n7), fully matched unrelated
(n9), or 7/8 DR-mismatched unrelated (n1) donors. The
Blood Dendritic Cell Enumeration Kit (Miltenyi Biotec, Inc.,
Auburn, CA) was used to identify the percentages of myeloid
DC1 (MDC1), plasmacytoid DC (PDC), and myeloid DC2
(MDC2) subpopulations within the non-B-cell, non-monocytic,
non-granulocytic gate in peripheral blood obtained before ini-
tiation and after completion of the preparative regimen. Re-
sults: The median percentages of MDC1, PDC, and MDC2
cells were as follows: at initiation: 0.26%, 0.11%, and 0.07%
respectively, following ECP: 0.38%, 0.07%, and 0.01% respec-
tively, Day 0: 0.07%, 0%, and 0% respectively. Following ECP,
the median change in MDC1, PDC, and MDC2 cells were 0%,
-58%, and -65% respectively. On Day 0, the median change in
MDC1, PDC, and MDC2 cells were -49%, -96%, and -73%
respectively among ECP-based regimens, and -98%, -100%,
-100% respectively among conventional regimens (p0.73,
p0.30, p0.09 respectively). The median ratios of MDC1 to
PDC cells were 2.5 pre-transplant, 3.6 following ECP, and 0.56
on Day 0. ECP decreased at least 1 DC lineage by 100% in 50%
of patients, but decreased all 3 DC lineages by 100% in only
10% of patients. By Day 0, 76% of patients had at least 1 DC
lineage decreased by 100%, and 24% of patients had all 3 DC
lineages decrease by 100%. Conclusions: Preparative regimens
can decrease all 3 subtypes of host DCs pre-transplant. The
effects of ECP on host DCs may be delayed since the decrease
in DC percentages and the shift from a high, pro-inﬂammatory,
DC1/DC2 ratio to a low, pro-tolerogenic DC1/DC2 ratio did
not occur until day 0. The effects of changes in pre-transplant
host DC populations on GVHD outcomes require further
study.
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RADIOPROTECTION BY GROWTH HORMONE
Chen, B.J.1, Deoliveira, D.1, Chao, N.J.1 1Duke University Medical
Center, Durham, NC.
Hematopoietic and immune systems are sensitive to ionizing
irradiation and the recovery is slow. Very few effective therapeutic
agents are currently available for this condition. In this study, we
investigated the effects of growth hormone on hematopoietic and
immune recovery post irradiation and its ability to protect against
lethal irradiation. The studies were performed using BALB/c mice.
Recombinant human growth hormone (rhGH) was given at the
dose of 20 	g/dose, i.p. or i.v., once a day, starting within one hour
after irradiation. The hematologic and immune recovery was mon-
itored weekly post irradiation. In a sublethally irradiated (5 Gy)
model, treatment with rhGH for 30 days signiﬁcantly accelerated
the recovery of platelets in peripheral blood (5908713860 vs.
428257425 on day 8, P0.01). Similar trends were also ob-
served in total white blood cells and all lymphocyte subsets tested
(T, B, NK cells). Similar results were obtained when higher dose of
radiation dose (7.5 Gy) was used. These data suggest that growth
hormone can promote hematopoietic and immune recovery after
irradiation. We next tested whether growth hormone can rescue
animals from lethal irradiation. BALB/c mice were irradiated with
7.5 Gy and treated with rhGH for 35 days. As demonstrated in the
table, 13 out of 20 mice in the growth hormone treated group
survived more than 60 days after irradiation, whereas only 3 out of
20 mice survived more than 25 days in the saline control group.
The radioprotective effect was still observed when higher dose of
radiation (8.5 Gy) was used. These ﬁndings demonstrate that
growth hormone has signiﬁcant radioprotective effects even when
given after total body irradiation.
Growth hormone protects against lethal irradiation
Groups n Survival
day 25 day 60
Saline control 20 3/20 3/20
Growth hormone 20 16/20* 13/20*
*P0.01
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KIR2DS1 AND 2DS2 INDUCE NK CELL CYTOKINE RESPONSE AGAINST
ALLOGENEIC B-LYMPHOBLASTOID CELL LINES
Chewning, J.H.1, Gudme, C.N.2, Selvakumar, A.2, Dupont, B.2 1De-
partment of Pediatrics, Memorial Sloan-Kettering Cancer Center, New
York, NY; 2Immunology Program, Memorial Sloan-Kettering Cancer
Center, New York, NY.
NK cells reconstitute the host immune system early following
hematopoietic stem cell transplant (HSCT), and may act to pre-
vent relapse in patients receiving HSCT for malignant diseases.
NK cell effector mechanisms include both cytotoxicity and cyto-
kine secretion, and these functions result from different signaling
pathways following receptor-ligand interactions. We have previ-
ously shown KIR2DS1 and 2DS2 regulate cytotoxicity against
B-lymphoblastoid cell lines (BLCL) positive for HLA-Cw C2 or
C1 group antigens, respectively. Alloreactivity was only displayed
by NK cells from donors not expressing these same HLA antigens
in cis. In this study, we analyzed cytokine production by NK cells
from donors possessing the genes for 2DS1 and 2DS2, and ho-
mozygous for C1 or C2 group, respectively. IL2 propagated, poly-
clonal NK cells from 2DS1-positive, C1 donors secreted signiﬁ-
cantly higher levels of interferon-gamma (IFN-g) following
incubation with C2 group BLCL compared to C1 group BLCL.
Intracellular FACS staining revealed that the NK subset expressing
the 2DL1, S1 receptor was the IFN-g producing population. NK
clones obtained from these same donors demonstrated increased
production of IFN-g, TNF-alpha, and GM-CSF after 2DS1 re-
ceptor crosslinking. Intracellular FACS using freshly isolated NK
cells from 2DS1-positive, C1 donors again revealed increased
IFN-g production after incubation with C2 group BLCL or re-
ceptor cross-linking. Subset analysis within the NK population
revealed the IFN-g-positive cells were those NK cells expressing
both 2DL1, S1 and an additional inhibitory receptor recognizing
an autologous HLA class I ligand. The 2DS1, L1 subset lacking
these inhibitory receptors did not respond to BLCL or positive
controls. In addition, only 2DS1-positive NK clones co-expressing
inhibitory receptors for autologous HLA class I were obtained
from donor peripheral blood. Similar data was obtained with NK
cells from 2DS2 positive, C2 homozygous donor NK cells after
incubation with C1 group positive BLCL and following 2DS2
receptor crosslinking. We here present data demonstrating
KIR2DS1 and 2DS2 induce cytokine release against allogeneic
cells, and these receptors function only in those NK cells co-
expressing inhibitory receptors for autologous HLA class I ligand.
NK cell activation and cytokine production by activating KIR
could have important implications in disease relapse prevention
following HSCT, especially in the setting of HLA-Cw group
mismatch.
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